Latest News

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is mmoldering inflammation in MS!

Christina Xia, MD, a stroke specialist at Cleveland Clinic, reviewed recent advances in stroke rehabilitation, including neuromodulation and emerging approaches aimed at improving long-term recovery after stroke.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 29, 2026.

New data presented at CMSC 2026 suggest ocrelizumab provides comparable relapse and MRI control in pediatric- and young-adult–onset multiple sclerosis, with greater disability improvement observed in pediatric patients.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Todd Arnedt, PhD. [LISTEN TIME: 18 minutes]

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed important behind the scenes work nurses carry out in neurology care.

German 3-year real-world data shows ozanimod keeps RRMS relapses low, disability stable, and safety consistent in routine care.

A literature review suggests ferritin may serve as a “dual-edged” biomarker in multiple sclerosis, with elevated levels associated with disease progression and low levels linked to impaired remyelination.

Three-year extension data presented at CMSC 2026 showed sustained suppression of MRI activity and low relapse rates with frexalimab in relapsing multiple sclerosis.

A new analysis presented at CMSC 2026 suggests that rescue treatment with complement inhibition may help stabilize disease activity in Hispanic patients with NMOSD who experienced relapse despite treatment.

A real-world study presented at CMSC 2026 reported year-1 improvements in treatment satisfaction and disease impact measures in patients with MS treated with ublituximab.

An analysis from the phase 3b ENLIGHTEN study presented at the 2026 CMSC Annual Meeting showed that cognitive performance remained stable during long-term treatment with ozanimod in patients with relapsing multiple sclerosis.